Watchlist Price Alert

Axsome Therapeutics Inc. (AXSM)

NASDAQ: AXSM · Real-Time Price · USD

107.71

-1.15 (-1.06%)

At close: May 09, 2025, 3:59 PM

107.76

0.05%

After-hours: May 09, 2025, 05:17 PM EDT

-1.06% (1D)

Bid	105
Market Cap	5.3B
Revenue (ttm)	432.16M
Net Income (ttm)	-278.27M
EPS (ttm)	-5.76
PE Ratio (ttm)	-18.7
Forward PE	45.65
Analyst	Buy

Ask	110
Volume	331,767
Avg. Volume (20D)	865,468
Open	108.86
Previous Close	108.86
Day's Range	107.70 - 110.16
52-Week Range	64.11 - 139.13
Beta	0.45

About AXSM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AXSM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AXSM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Axsome Therapeutics has released their quartely earnings on May 5, 2025:

Revenue of $121.46M exceeds estimates by $2.18M, with 61.95% YoY growth.

EPS of -0.68 exceeds estimates by 0.67, with 32.00% YoY growth.

Why Price Moved

4 days ago

+3.81%

Axsome Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

1 month ago

-4.25%

Axsome Therapeutics shares are trading lower after the company's Solriamfetol failed its primary goal in depression study but showed improvements in associated sleep disorder.

News

3 days ago · seekingalpha.com

Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns

Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the competit...

3 days ago · zacks.com

AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.

4 days ago · seekingalpha.com

Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Piz...

4 days ago · benzinga.com

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

Axsome Therapeutics Inc AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million.

4 days ago · zacks.com

Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to...

4 days ago · zacks.com

Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.09 per share a year ago.

1 week ago · zacks.com

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago · zacks.com

Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?

Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the...

1 month ago · zacks.com

AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol

Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.

1 month ago · fool.com

Why Shares of Axsome Therapeutics Slumped Today

Shares of biopharmaceutical company Axsome Therapeutics (AXSM -6.29%) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (b...

Load More News